TY - JOUR
T1 - Retrieval of patients with hepatitis C who were lost to follow-up in Southern Denmark
AU - Dröse, Sandra
AU - Hansen, Janne Fuglsang
AU - Røge, Birgit Thorup
AU - Øvrehus, Anne Lindebo Holm
AU - Christensen, Peer Brehm
N1 - Funding Information:
The C-Free South Project is funded by the C.H.I.M.E. grant by Gilead Sciences [ISR-DK-18-10469]. The Region of Southern Denmark and the University of Southern Denmark, Odense, have supported the work. The financial supporters have not been involved in this work. The authors thank nurses Trine Sølund Bager and Mie Rønnebæk in the hepatitis outpatient clinic, Department of Infectious Disease, Odense University Hospital, and Department of Medicine, Sygehus Lillebælt, Kolding, for their great commitment.
Publisher Copyright:
© 2023 Society for Scandinavian Journal of Infectious Diseases.
PY - 2023/5
Y1 - 2023/5
N2 - BACKGROUND: The goal of the C-Free-South project is to eliminate hepatitis C (HCV) in the Region of Southern Denmark (1.2 million inhabitants). One target group consists of people with HCV who had received care but were lost to follow-up. The study aim was to evaluate program efficacy in locating these patients and getting them into care.METHODS: Patients were contacted if they were HCV-RNA positive and age 18+ years, registered in the clinical hepatitis database as of November 1, 2019, and had no scheduled HCV-related appointment. They were contacted at 2-month intervals by phone or letter. For patients who did not respond, we asked their general practitioner to refer them, if possible.RESULTS: We identified 69 (7%) patients in the database who were listed as untreated and not being followed up. We successfully contacted 54 (78%), and the remaining 15 (22%) did not respond to our contacts. To date, 45 (65%) had initiated treatment, one (1%) had rejected treatment, and eight (12%) did not show up to their appointments. Among those receiving treatment, 20 (44%) responded after the first contact, 18 (40%) after the second contact, and 7 (16%) after informing the general practitioner.CONCLUSION: An intensified and persistent effort made it possible to reach most HCV patients lost to follow-up. All new contact attempts increased the possibility that patients would receive treatment. Nevertheless, 22% of HCV patients lost to follow-up did not respond to repeated contact attempts.
AB - BACKGROUND: The goal of the C-Free-South project is to eliminate hepatitis C (HCV) in the Region of Southern Denmark (1.2 million inhabitants). One target group consists of people with HCV who had received care but were lost to follow-up. The study aim was to evaluate program efficacy in locating these patients and getting them into care.METHODS: Patients were contacted if they were HCV-RNA positive and age 18+ years, registered in the clinical hepatitis database as of November 1, 2019, and had no scheduled HCV-related appointment. They were contacted at 2-month intervals by phone or letter. For patients who did not respond, we asked their general practitioner to refer them, if possible.RESULTS: We identified 69 (7%) patients in the database who were listed as untreated and not being followed up. We successfully contacted 54 (78%), and the remaining 15 (22%) did not respond to our contacts. To date, 45 (65%) had initiated treatment, one (1%) had rejected treatment, and eight (12%) did not show up to their appointments. Among those receiving treatment, 20 (44%) responded after the first contact, 18 (40%) after the second contact, and 7 (16%) after informing the general practitioner.CONCLUSION: An intensified and persistent effort made it possible to reach most HCV patients lost to follow-up. All new contact attempts increased the possibility that patients would receive treatment. Nevertheless, 22% of HCV patients lost to follow-up did not respond to repeated contact attempts.
KW - direct-acting antivirals
KW - Hepatitis C
KW - lost to follow-up
KW - micro-elimination
KW - retrieval
KW - Lost to Follow-Up
KW - Hepacivirus/genetics
KW - Hepatitis C/epidemiology
KW - Humans
KW - Denmark/epidemiology
KW - Antiviral Agents/therapeutic use
KW - Adolescent
KW - Hepatitis C, Chronic/drug therapy
U2 - 10.1080/23744235.2023.2189298
DO - 10.1080/23744235.2023.2189298
M3 - Journal article
C2 - 36930953
SN - 2374-4235
VL - 55
SP - 361
EP - 369
JO - Infectious Diseases
JF - Infectious Diseases
IS - 5
ER -